

UNITED STATES DEPARTMENT OF COMMERCE **Patent and Trademark Offic**

COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

| | APPLICATION NO. | FILING DATE | FIRST NAMED INV | ENTOR | tol A | ATTORNEY DOCKET NO. |
|---|---|-----------------------|-----------------|-------|-----------|-------------------------------|
| | U9/105, I.L. | 7 06/1//98 | VIAIm destric | | | S Sulfation and State Control |
| Г | KLAUS J BACH 4407 TWIN OAKS LANE MURRYSVILLE PA 15668 | | HM32/0909 | | STOLE | XAMINER |
| | | | | | ART UNIT. | PAPER NUMBER |

09/09/99

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks



UNIT STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

| SERIAL NUMBER | FILING DATE | FIRST NAMED APP | LICANT | ATTORNEY DOCKET NO. |
|---------------|-------------|-----------------|-----------|---------------------|
| | | | | |
| | | 1 | | |
| | | | Е | XAMINER |
| | | ļ | | |
| | | | ART UNIT | PAPER NUMBER |
| | | | · | 14 |
| | | , <u>L</u> | DATE MAIL | ED: |

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response. The Group and Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1653.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Einar Stole, Ph.D., whose telephone number is (703) -305-4507. The Examiner can normally be reached Tuesday through Friday 6:30 a.m. to 5:00 p.m.

If attempts to reach the Examiner are unsuccessful, the Examiner's supervisor, Bradley Sisson, can be reached on (703)-308-3978. The fax phone number for Technology Center 1600 is (703)-305-7401.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703)-308-0196.

EMAR STOLE, PH.D PATENT EXAMINER

September 8, 1999

Application No.: 09/105,117

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

| | This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990. |
|-----|---|
| | 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). |
| | 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). |
| X | 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." |
| | 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). |
| | 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). |
| | 7. Other: |
| Apı | olicant Must Provide: |
| X | A substitute computer readable form (CRF) copy of the "Sequence Listing". |
| X | An substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. |
| X | A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). |
| For | questions regarding compliance to these requirements, please contact: |
| For | Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 PatentIn software help, call (703) 308-6856 |

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE